FindTrial
Sign In

Efficacy of Integrated Traditional Chinese and Western Medicine in the Treatment of Patients with Primary Lung Cancer: A Prospective Observational Cohort Study

Optimization of an Integrated Traditional Chinese and Western Medicine Diagnostic and Treatment Model for Lung Cancer and Identification of Benefiting Populations Based on Multi-source Heterogeneous Data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001558
Enrollment
Unknown
Registered
2026-06-20
Start date
2026-05-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

No group:None

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 80 years old; (2) Patients pathologically or cytologically diagnosed with primary lung cancer in accordance with CSCO Guidelines for Clinical Diagnosis and Treatment of Common Malignant Tumors (2025 Edition); (3) Receiving integrated traditional Chinese and Western medicine (TCM-WM) therapy, defined as standard Western medicine combined with Chinese herbal decoctions, proprietary Chinese medicines and/or appropriate TCM techniques; (4) At early treatment stage upon initial enrollment, i.e., within ±2 weeks from the initiation of systematic integrated TCM-WM treatment; (5) Complete available data including four TCM diagnostic information (tongue manifestation, pulse condition, chief complaints and clinical symptoms), laboratory test results (blood routine, serum biochemistry, tumor markers, etc.), imaging or pathological findings (lesion size, metastatic status, etc.), as well as treatment and medication records (TCM prescriptions and Western medicine regimens). Data shall be structured and time-series with no less than two dynamic follow-up records; (6) Feasible for follow-up, with expected availability of follow-up or efficacy outcome data for no less than 6 months; (7) Voluntarily participating in this study and signing written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients complicated with other active malignant tumors or severe systemic diseases (such as liver cirrhosis, heart failure, mental disorders); (2) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Overall Survival;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30;—

Secondary

MeasureTime frame
Progression-Free Survival;Median Progression-Free Survival;Objective Response Rate;Disease Control Rate;Neutrophil-to-Lymphocyte Ratio;Platelet-to-Lymphocyte Ratio;C-reactive protein;Interleukin-6;Tumor Necrosis Factor-a;CD4/CD8 ratio;Albumin;Hemoglobin;Glucose;Lactate Dehydrogenase;Total Protein;Total Cholesterol;Carcinoembryonic Antigen;Cytokeratin 19 Fragment;Neuron-Specific Enolase;Cancer Antigen 125;Pro-gastrin-releasing peptide;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29;MD Anderson Symptom Inventory–Lung Cancer Module;—

Countries

China

Contacts

Public ContactPang Bo

Xiyuan Hospital, China Academy of Chinese Medical Sciences

drpangbo@gmail.com13810166354

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026